PT-141

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II — specifically the cyclic fragment that retains melanocortin receptor activity. It was the first drug ever approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi (FDA approved 2019). Unlike sildenafil (Viagra) and similar PDE5 inhibitors that work peripherally on blood flow, PT-141 works centrally by directly activating the brain's sexual arousal circuitry through melanocortin receptors, making it effective in both sexes and independent of vascular function.

PT-141 is a non-selective melanocortin receptor agonist with high affinity for MC3R (melanocortin 3 receptor) and MC4R (melanocortin 4 receptor) in the central nervous system. MC4R activation in the hypothalamus and limbic system directly modulates sexual desire, motivation, and arousal circuitry — the same receptors involved in energy homeostasis and reward behavior. This is a fundamentally different mechanism from PDE5 inhibitors: PT-141 increases libido and sexual motivation at the neurological level rather than simply increasing genital blood flow. Animal research demonstrates that MC4R activation increases sexual mounting behavior, partner preference, and copulatory frequency. PT-141 also has mild dopaminergic properties that contribute to motivation and reward signaling. Because it works centrally, it is effective in cases of psychological or neurological HSDD where vascular treatments fail.

PT-141 (bremelanotide) underwent formal Phase II and Phase III clinical trials by Palatin Technologies. The RECONNECT I and RECONNECT II Phase III trials in premenopausal women with HSDD (1,200+ subjects) demonstrated statistically significant improvements in desire and reductions in distress. Palatin received FDA approval in June 2019 (marketed as Vyleesi). The pivotal clinical program included studies of nasal spray formulations (discontinued due to blood pressure effects) and the approved subcutaneous autoinjector. Pharmacokinetic studies characterized the ~2.7 hour half-life and dose-proportional exposure. Studies in men demonstrated efficacy for erectile dysfunction via central mechanisms. The FDA approved drug label includes specific warnings for cardiovascular effects and nausea management.

On-Demand Sexual Wellness Protocol: PT-141 1.75 mg SC 45–90 minutes before activity, no more than once per 24 hours. Low Sensitivity Starter Protocol: 0.75 mg SC on first use, increasing to 1.25 mg, then 1.75 mg on subsequent uses to identify the minimum effective dose. Anti-nausea mitigation: take 8 mg oral ondansetron (Zofran) 30 minutes before PT-141 injection to substantially reduce nausea — a widely used practice in research communities.

Nausea is the most common side effect of PT-141, occurring in approximately 40% of users in clinical trials — severity ranges from mild to significant, particularly at doses above 1.75 mg. Flushing (warmth, skin redness) and a transient, moderate increase in blood pressure (systolic BP increase of ~6–14 mmHg lasting 30–60 minutes) are consistent findings. For this reason, PT-141 is contraindicated in patients with cardiovascular disease or uncontrolled hypertension. Headache is reported in approximately 10% of users. Yawning — a curious and distinctive side effect — is commonly reported and is actually associated with melanocortin-mediated dopamine release (it is also seen with other MC4R agonists). Fatigue after the effect resolves is occasionally noted. Hyperpigmentation is not reported at these doses (unlike Melanotan II), as the doses used are insufficient to meaningfully stimulate skin melanocytes.

Store lyophilized PT-141 at 2–8°C, protected from light. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. The Vyleesi autoinjector should be stored at room temperature below 30°C and not refrigerated. Protect all forms from heat and direct sunlight. A standard reconstitution: 2 mg vial + 1 mL BAC water yields 2,000 mcg/mL (2 mg/mL). On a U-100 syringe: 1 mg = 50 units.